Other three validated AML-PDX models, AM8096 (M2 subtype with RUNX1-RUNX1T1 fusion and CEBPA mutation), AM5512 (M7 subtype) and AM7407 (M4 subtype with KMT2A rearrangement) (Supplement Table S1) are also similarly suitable for pharmacology modeling. The gene discussed is KMT2A; the disease is acute myeloid leukemia.